Osteoprotegerin variant proteins

Details Osteoprotegerin variant proteins Osteoprotegerin variant proteins

2005-12-13

2009-11-03

Kemmerer, Elizabeth C (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C514S002600, C514S012200, C514S008100, C536S023100, C536S023500

Reexamination Certificate

active

07612169

ABSTRACT:
The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6613644 (2003-09-01), Lachner
patent: 2003/0207827 (2003-11-01), Boyle
patent: 2003/0219864 (2003-11-01), Desjarlais
patent: WO 99/58661 (1999-11-01), None
patent: WO 02/064782 (2002-08-01), None
patent: WO 2004/039995 (2004-05-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 491-495.
Adler et al., (2002) “Immunotherapy as a Means to Induce Transplantation Tolerance.”Current Opinion in Immunology, 14: 660-665.
Anderson et al. (1997) “A Homologue of the TNF Receptor and its Ligand Enhance T-Cell Growth and Dendritic-Cell Function.”Nature, 390(6656): 175-179.
Atkins et al., (2001) “Osteoprotegerin Inhibits Osteoclast Formation and Bone Resorbing Activity in Giant Cell Tumors of Bone.”Bone, 28: 370-437.
Bekker et al., (2001) “The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women.”Journal of Bone Mineral Research, 16: 348-60.
Body et al., (2003) “A Phase I Study of AMGN-007, a Recombinant Osteoprotegerin Construct, in Patients with Multiple Myeloma or Breast Carcinoma Related Bone Metastases.”Cancer, 97: 887-92.
Bolon et al., (2002) “Duration of Bone Protection by a Single Osteoprotegerin Injection in Rats with Adjuvant-Induced Arthritis.” Cellular and Molecular Life Sciences, 59: 1569-1576.
Cheng et al., (2003) “Disabling of Receptor Activator of Nuclear Factor-kB (RANK) Receptor Complex by Novel Osteoprotegerin-Like Peptidomimetics Restores Bone Loss in Vivo,”The Journal of Biological Chemistry, 279: 8269-8277.
Coia et al., (1996) “Construction of Recombinant Extended Single-Chain Antibody Peptide Conjugates for Use in the Diagnosis of HIV-1 and HIV-2,”Journal of Immunological Methods, 192: 13-23.
Cross et al. (2005)“Osteoprotegerin (OPG)—A Potential New Role in the Regulation of Endothelialcell Phonotype and Tumour Angiogenesis”International Journal of Cancer,, Nov. 14, 2005 (epub).
Croucher et al. (2001) “Osteoprotegerin Inhibits the Development of Osteolytic Bone Disease in Multiple Myeloma,”Blood, 98: 3524-3540.
Daroszewska et al. (2004) “Susceptibility to Paget's Disease of Bone is Influenced by a Common Polymorphic Variant of Osteoprotegerin,”Journal of Bone and Mineral Research,. 19: 1506-11.
Doran et al. (2004) “Native Osteoprotegerin Gene Transfer Inhibits the Development of Murine Osteolyt ic Bone Disease Induced by Tumor Xenografts.”Experimental. Hematorlogy, 32: 351-59.
Emery et al. (1998) “Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL,”The Journal of Biological Chemistry, 273: 14363-14367.
Gardnerova et al. (2000) “The Use of TNF Family Ligands and Receptors and Agents Which Modify Their Interaction as Therapeutic Agents,”Current Drug Targets, 1: 327-364.
Guiliani et al., (2004) “New Insight in the Mechanism of Osteoclast Activation and Formation in Multiple Myeloma: Focus on the Receptor Activator of NF-kB Ligand (FRANKL),”Experimental Hematology, 32: 685-691.
He et al. (2004) “Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor.”Science, 304: 870-875.
Hofbauer et al. (2001) “Receptor Activator of Nuclear Factor-kB Ligand and Osteoprotegerin.”Cancer Research, 92(3): 460-470.
Hofbauer et al. (2004) “Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases,”Journal of the American Medical Association, 292:490-495.
Holen et al. (2002) “Osteoprotegerin (OPG) is a Survival Factor for Human Prostate Cancer Cells,”Cancer Research, 62: 1619-1623.
Honore et al. (2000) “Osteoprotegerin Block Bone Cancer-Induced Skeletal Destructions, Skeletal Pain and Pain-Related Neurochemical Reorganization of the Spinal Cord,”Nature Medicine, 6(5): 521-528.
Hsu et al. (1999) “Tumor Necrosis Factor Receptor Family Member RANK Mediates Osteoclast Differentiation and activation Induced by Osteoprotegerin Ligand,”Proceedings of the National Academy of Sciences, USA, 96: 3540-3545.
Hymowitz et al. (1999) “Triggering Cell Death: The Crystal Structure of Apo2I/TRAIL in a Complex with Death Receptor 5,”Molecular Cell, 4: 563-571.
Igney et al. (2002) “Death and Anti-Death: Tumour Resistance to Apoptosis,”Nature, Reviews/Cancer, 2: 277-288.
Ito et al. (2002) “Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2- Å Resolution,”Journal of Biological Chemistry, 277: 6631-6636.
Kaden et al. (2004) “Unbalanced RANKL/RANK Pathway in Aortic Valve Sclerosis,”Journal of Moecular and Cellular Cardiology, 36: 17-19.
Kong et al. (1999) “OPGL is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-Node Organogenesis,”Nature, 397: 315-323.
Kostenuik et al. (2001) “OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats,”Endocrinology, 142: 4295-4304.
Lacey et al. (2000) “Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo,”American Journal of Pathology, 157: 435-448.
Lacey et al. (1998) “Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation,”Cell, 93: 165-176.
Liu et al. (2004) “Production of Recombinant Human Osteoprotegerin From Trichoplusia NI Cells and Bombyx Mori Larvae,”Protein and Peptide Letters11: 317-323.
Lorenz et al., (2004) “Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases.”Journal of the American Medical Association, 292: 490-495.
Luger et al. (2001) “Osteoprotegerin Diminishes Advanced Bone Cancer Pain,”Cancer Research, 61: 4038-4047.
Mitsiades et al. (2002) “Activation of NF-KB and Upregulation of Intracellular Anti-Apoptotic Proteins Via the IGF-1/Akt Signaling in Human Multiple Myeloma Cells: Therapeutic Implications,”Oncogene, 21: 5673-5683.
Mongkolsapaya et al., (1999)“Structure of the TRAIL-DR5 Complex Reveals Mechanisms Conferring Specificity in Apoptotic Initiation,”Nature Structural Biology, 6: 1048-1053.
Morony et al., (1999) “A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by II-1β, TNF-α, PTH, PTHrP, and 1,25 (OH)2D3,” Journal of Bone and Mineral Research, 14: 1478-1485.
Mundy et al. (2002) “Metastasis to Bone: Causes, Consequences and Therapeutic Opportunities,”Nature Reviews Cancer, 2: 584-593.
Neville-Webbe et al., (2004) “Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects B

Affiliated with

Also associated with

Rating

Osteoprotegerin variant proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osteoprotegerin variant proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteoprotegerin variant proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4133041